



## Original Research Article

### Antimicrobial activity of a thermotolerant *Aureobasidium pullulans* strain isolated from Faizabad region of Uttar Pradesh in India

Ranjan Singh<sup>1\*</sup>, Rajeeva Gaur<sup>2</sup>, Manogya Kumar Gaur<sup>3</sup>,  
Prabhash K. Pandey<sup>4</sup> and Farrukh Jamal<sup>4</sup>

<sup>1</sup>Department of Botany and Microbiology, St. Aloysius (Autonomous) College,  
Jabalpur, M.P., India

<sup>2</sup>Department of Microbiology (DST-FIST Supported, Center of Excellence), Dr. R.M.L. Avadh  
University, Faizabad, U.P. India

<sup>3</sup>D.G.M. Environment, Balarampur Distillery, Babhanan, Basti, U.P., India

<sup>4</sup>Department of Biochemistry, Dr. R.M.L. Avadh University, Faizabad, U.P., India

\*Corresponding author

#### A B S T R A C T

#### Keywords

*Aureobasidium pullulans*,  
Antimicrobial  
Activity,

A thermotolerant strain of *Aureobasidium pullulans* was isolated from a flower sample during summer season which showed activity against gram-negative bacteria, but could not inhibit *Staphylococcus aureus* and *Bacillus* species. The results clearly indicate that *A. pullulans* has a good antimicrobial activity against some pathogenic microorganisms and can prove to be good antibiotic producing organism in future.

#### Introduction

*Aureobasidium pullulans* (De Bary) Arnaud is a cosmopolitan yeast like fungus that occur in diverse habitats, including the phyllosphere of many plants and also on various tropical fruits (Gaur et al., 2010). *A. pullulans* is industrially important because of its capacity to produce the polysaccharide "pullulan" (Singh et al., 2012). It is a linear  $\alpha$ -D-glucan, made mainly of maltotriose repeating units interconnected by  $\alpha$ -1,6 linkages. The regular alternation of  $\alpha$ -1,4 and  $\alpha$ -1,6 bonds results in two distinctive properties that is structural flexibility and enhanced solubility (Leathers, 2002). This polysaccharide is of great economic importance with increased applications in

food, pharmaceutical, agricultural, blood plasma substitute and chemical industries (Cheng et al., 2009, Sena et al., 2006). Pullulan produces a high viscosity solution at a relatively low concentration and can be used for oxygen-impermeable films and fibers, thickening or extending or adhesives or encapsulating agents (Lazaridou et al., 2002). World Health organization has placed *A. pullulans* within risk "Group I" (W.H.O. Weekly Epidemiological Records, 1994), where there is no possibility of infection to either society or laboratory workers. A large number of bioactive and structurally diverse fungal metabolites have been isolated and characterized and some of these have been

used for the development of valuable pharmaceuticals and pesticides. Of the estimated 1.5 million species of fungi recorded worldwide, approximately 4,000 secondary metabolites of fungal origin are known to possess biological activities (Strobel and Daisy, 2003); the vast majority coming from the species of *Penicillium*, *Aspergillus*, *Acremonium* and *Fusarium* (Schulz et al., 2002). There are relatively few reports on antimicrobial compounds obtained from various yeasts and yeast-like fungi. Few reports are available on antimicrobial activity of *A. pullulans* (Kalantar et al., 2006, Weilin et al, 2009, Sepcic et al, 2011, Price et al, 2013). McCormack et al., (1994) reported for the first time the inhibition of *P. aeruginosa* and *Staphylococcus aureus* by compounds obtained from *A. pullulans*. Takesako et al., (1993) reported a group of antifungal antibiotics, named aureobasidins, from *A. pullulans*. *A. pullulans* appears to be a promising organism for development of newer antimicrobial agents, both for chemotherapy as well as non-medical applications. A large number of bioactive and structurally diverse fungal metabolites have been isolated and characterized and some of these have been used for the development of valuable pharmaceuticals and pesticides.

On the basis of the above observation a thermotolerant strain of *A. pullulans*, RG-5, (MTCC NO. 9605) was subjected to antimicrobial activity against some pathogenic bacterial and fungal strain.

## **Materials and Methods**

### **Isolation and Maintenance of Micro-organism:**

*A. pullulans* was isolated from the flower and leaves samples collected nearby

university campus. Isolation was done by selective enrichment method as followed by Pollock et al., (1992). Flowers and leaves samples were soaked in sterile water for 3 days at 35°C, and then 0.1 ml was transferred to 10 ml of basal fungal medium (pH 5.0). After 2 days the turbid cultures were allowed to sit undisturbed for 20 minutes to allow filaments and aggregates to settle to the bottom. About 10µl from the upper, partially clarified phase that was enriched for yeast like cells was spread onto agar plates containing Glucose, 2.0%; Ammonium Sulphate, 0.06%; di-Potassium Hydrogen Orthophosphate, 0.5%; Sodium Chloride, 0.1%; Magnesium Sulphate, 0.04% and Yeast Extract, 0.04% with pH - 5.0.(Qualigens Chemicals, Mumbai, Maharashtra, India). Isolates were maintained on the same medium at 4°C in slants and sub-cultured monthly. The isolates were identified on the basis of morphological and cultural characteristics using standard identification manuals of fungi (Kurtzman and Fell, 1998) on its respective medium.

### **Growth Conditions and Fermentation:**

For this the method of Kalanter et al., (2006) was followed. A loopful of cells ( $10^8$  cells/ml) taken from the slant culture of *A. pullulans* were suspended in three ml of sterile distilled water. From this suspension one ml was transferred into 10 ml of Sabouraud Dextrose Broth (SDB), incubated for 48h on a shaker set at 120 rpm, in order to prepare inoculums. One ml of the inoculum was added to 100 ml of malt extract broth and incubated at 28°C on a shaker set at 120 rpm for three days. The entire content of the flask was centrifuged at 5000 rpm for 20 min and the supernatant was extracted three times with 10 ml of ethyl acetate, concentrated up to 2 ml under a stream of nitrogen gas and then used for testing the antimicrobial activity.

Testing the antimicrobial activity: Antimicrobial activity of the above extract was determined by the disc assay procedure (Jacques and Goldstein, 1986). The concentrated ethyl acetate extract (100  $\mu$ l) was added to an ampoule containing 10 sterile disks (Whatman paper number 1; 5 mm diameter) and kept in a refrigerator for 24 h. Control disks were prepared using an ethyl acetate extract of the uninoculated medium.

Microorganisms: The antibiotic assays were performed using *Acinetobacter calcoaceticus*, *Bacillus subtilis*, *Escherichia coli*, *Klebsiella pneumoniae*, *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Salmonella typhi*, *Trichophyton rubrum*, *Candida albicans*, *Saccharomyces cerevisiae* and *Pichia angusta*. All the microorganisms were obtained from Institute of Microbial Technology (IMTECH), Chandigarh, India. The bacterial and fungal strains were maintained on Muller Hilton Agar and Sabouraud Dextrose agar, respectively.

## Result and Discussion

The fungal strain showed activity against gram-negative bacteria, but could not inhibit *Staphylococcus aureus* and *Bacillus* species. Strikingly, Pseudomonas seem to be apparently much more sensitive to *A. pullulans*. An emerging nosocomial pathogen, *Acinetobacter calcoaceticus* was also inhibited by *A. pullulans*. Similarly, *E.coli*, *S. typhi* and *K. pneumoniae* was also inhibited by this fungus. This particular strain of *A.pullulans* inhibited *P. angusta* but could not inhibit *C. albicans* and *S. cerevisiae* (Table 1).

Production of antibiotic has been reported most often from the eubacteria-like *Bacillus*, Actinomycetes, e.g. *Streptomyces* and from lower fungi e.g. *Cephalosporium*. It

should be pointed out that more than 3000 antibiotics have been isolated from actinomycetes and relatively few from fungi (Giancarlo and Francesco, 1982). Mac William (1995) has found that yeasts and yeast-like fungi, as compared to other microorganisms, are not a promising source of novel antibiotics.

Because of the emergence of pathogens resistant to most currently available antimicrobial agents and a concomitant increase in the number of immunosuppressed patients, screening of antimicrobial compounds is becoming increasingly important. This study provides comprehensive evidence that *A. pullulans* could be a promising producer of antimicrobial compounds. In this study the antimicrobial activity of *A. pullulans* strain was predominantly against gram-negative bacteria and *Pseudomonas* species. In particular and unlike the study of McCormack et al., (1994), no activity was seen against *Staphylococcus aureus*. It is worth noting that *Pseudomonas aeruginosa* has been a notorious organism for chemotherapy. It is highly resistant to  $\beta$ -lactam antibiotics and intractable to treatment with most potent antipseudomonal agents (Vasil et al., 1990).

The toxicity of the fungal metabolites herein screened to *P. aeruginosa* is of biological interest. Some strains causing septicemia and pneumonia in cystic fibrosis and immuno-compromised patients are becoming difficult to treat with available antimicrobial agents (Lory, 1990). Due to multi-resistance of this bacterium, there is a lack of active antibiotics effective against it, resulting in an increase in nosocomial infections and high mortality. Sequel to these facts, fungi as *A. pullulans* effect against *P. aeruginosa*, is proper candidates to search for new principals. Also, the fact that extracts from these fungi exhibit

activities against some of the microorganisms implicated in the pathogenesis of skin diseases (yeast such as *Candida albicans* and Dermatophytes such as *T. rubrum*) provides some scientific basis for the utilization of substances from these

two fungi for the treatment of skin disease. The result clearly indicates that *A. pullulans* has good antimicrobial activity against a number of microorganisms and can prove to be good antibiotic producing organism in future.

**Table.1** Antimicrobial activity of *A. pullulans* strains judged as the diameter (mm) of the inhibition zone

| Target Organism                   | Zone of Inhibition (mm) |
|-----------------------------------|-------------------------|
| <i>Eschericia coli</i>            | 10                      |
| <i>Pseudomonas aeruginosa</i>     | 5                       |
| <i>Salmonella typhi</i>           | 10                      |
| <i>Acinetobacter calcoaeticus</i> | 11                      |
| <i>Klebsiella pneumonia</i>       | 10                      |
| <i>Staphylococcus aureus</i>      | 0                       |
| <i>Bacillus subtilis</i>          | 0                       |
| <i>Candida albicans</i>           | 0                       |
| <i>Saccharomyces cerevisiae</i>   | 0                       |
| <i>Trichophyton rubrum</i>        | 0                       |
| <i>Pichia angusta</i>             | 5                       |

### Acknowledgment

Corresponding Author (Ranjan Singh) is thankful to University Grants Commission, (Ministry of HRD, Government of India) New Delhi for the financial support in the form of major research project in the area.

### References

Cheng, K.C., Demirci, A and Catchmark, J. (2009). Effect of temperature, Carbon Sources, Yeast Extract, and pH on Pullulan Production by *Aureobasidium pullulans*. American Soci. Agri. Biol. Eng. 2009 Reno, Nevada, June 21-24.096033.

Gaur R., Singh R., Gupta M. and Gaur M.K. (2010). *Aureobasidium pullulans*, an economically important polymorphic yeast with special reference to pullulan. Afr. J. Biotechnol. 9 (47), 7989-79997.

Giancarlo, L and Francesco P. (1982). Antibiotic and Producer organism. In: Antibiotics an Integrated View. (Ed.) Mortmer P. Starr. Springer-Verlang, New York. 236-241.

Jacques, F.A. and Goldstein F.W. (1986). Disk Susceptibility Test. In: Antibiotics in Laboratory Medicines. (Ed.) Victor Lorian. William and Wilkins. U.S.A. 27-63.

Kalantar, E., Deopurkar, R. and Kapadnis, B. (2006). Antimicrobial Activity of of Indigenous Strains of *Aureobasidium* Isolated from *Santalum Album* Leaves. Iranian J. Pharma. Research. 1: 59-64.

Kurtmam, C.P. and Fell, J.W. (1998). The Yeast: a taxonomic study. Elsevier. The Netherlands: 45-104.

Lazaridou, A., Biliaderies, C.G., Roukas, T., Izydorcyk, M. (2002). Production and characterization of pullulan from beet molasses using a nonpigmented strain

- of *Aureobasidium pullulans* in batch culture. *Appl. Biochem. Biotech.* 97, 1-22.
- Leathers, T.D. (2002). Pullulan. In: (Ed.) Vandamme, E.J., De. Baets, S., Steinbuchel, A. *Biopolymers. Polysaccharides II: Polysaccharides from Eukaryotes.* Wiley-VCH, Weinheim. 6, 1-35.
- Lory, S. (1990). *Pseudomonas* and other Nonfermenting Bacilli. In: (Ed.) Davis, B.D., Dulberco, R., Esien, H.N. and Ginsberg H.S. *Microbiology.* Lippincott Co., Philadelphia. 595.
- McCormack, P., Howard, G. and Jefferies, P. (1994). Production of antimicrobial compounds by phylloplane inhabiting yeasts and yeast like fungi. *Appl. Environ. Microbiol.* 60: 927-931.
- McWilliam, I.C. (1995). A survey of the antibiotic power of yeast. *J. Gen. Microbiol.* 21: 410-414.
- Pollock, T.J., Thorne, L. and Armentrout W.R. (1992). Isolation of new *Aureobasidium* strains that produce high-molecular-weight pullulan with reduced pigmentation. *Appl. Environ. Microbiol.* 58: 877-883.
- Price, N.P.J., Manitchotpisit, P., Vermillion, K. E., Bowman, M.J. and Leathers, T.D. (2013). Structural characterization of novel extracellular liamocins (mannitol oils) produced by *Aureobasidium pullulans* strain NRRL 50380. *Carbohydr. Res.* 370: 24-32.
- Schulz, S., Boyle, C., Draeger, S., Rommert, A. and Krochn, K. (2002). Endophytic fungi. A source of novel biologically active secondary metabolite. *Mycol. Res.* 106: 996-1004.
- Sena, R.F., Costelli, M.C., Gibson, L.H. and Coughlin, R.W. (2006). Enhanced production of pullulan by two strains of *Aureobasidium pullulans* with different concentration of soyabean oil in sucrose solution in batch fermentation. *Brazilian J. Chem. Eng.* 23: 507-515.
- Sepeic, K., Zalar, P. and Gunde-Cimerman, N. (2011). Low water activity induces the production of bioactive metabolites in halophilic and halotolerant fungi. *Mar Drugs.* 9: 43-58.
- Singh, R., Gaur, R., Tiwari, S. and Gaur, M.K. (2012). Production of pullulan by a thermotolerant *Aureobasidium pullulans* strain in non-stirred fed batch fermentation process. *Brazilian J. Microbiol.* 43: 1042-1050.
- Strobel, G. and Daisy, B. (2003). Bioprospecting for microbial endophytes and their natural products. *Microbiol. Mol. Biol. Rev.* 674: 491-502.
- Takesako, K., Ikai, K., Haruna, F., Endo, M., Shimanaka, K., Sono, E., Nakamura, T., Kato, I. and Yamaguchi, H. (1991). Aureobasidins, new antifungal antibiotics. Taxonomy, fermentation, isolation and properties. *J. Antibiot. (Tokyo).* 44: 919-924.
- Vasil, M., Arthur, E.P. and Rachel, M.O. (1990). Molecular Biology of Exotoxin A and Phospholipase C of *Pseudomonas*. In: *Pseudomonas, Biotransformations, Pathogenesis and Evolving Biotechnology.* (Ed.) Simon S., Chakrabarty A., Barbara I. and Samuel K. Merican Society for microbiology. Washington, D.C. 3-14.
- Weilin, W., Zhe, C., Guanglei, L., Muhammad, A.B., Zhenming, C. and Qianqun, G. (2009). Chemical and biological characterization of siderophore produced by the marine-derived *Aureobasidium pullulans* HN 6.2 and its antibacterial activity. *Biometals.* 22: 965-972.
- World Health Organization Weekly Epidemiological Records. (1994). 40: 340.